Akero Looks To Accelerate Path To Pivotal NASH Data With Phase IIb/III Protocol
89Bio Builds Case For Safety Advantage As FGF Competition Heats Up
Akero gets FDA’s ok to conduct Phase IIb/III study of FGF21 analog efruxifermin in biopsy-confirmed non-alcoholic steatohepatitis patients. With NASH leadership up in the air, Akero, 89bio and other FGF analog sponsors jockey for top spot.
